Pathologic Function
TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP
TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction
Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling
Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial
Distinguishing Adverse Events from Complications in Heart Attacks
heart attack, adverse event, complication, cardiac health, medical emergency
Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs
Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
Dupixent (Dupilumab) Shows Promising Results in Treating Bullous Pemphigoid, Paving Way for Regulatory Submissions
Dupixent, Dupilumab, Bullous Pemphigoid, Autoimmune Disease, Biologic Treatment, Type 2 Inflammation
Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer
Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease
GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half
GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation
Dyne Therapeutics Faces Setbacks Despite Promising DMD Study Results
Dyne Therapeutics, Duchenne Muscular Dystrophy (DMD), DELIVER trial, DYNE-251, adverse events, executive departures